Photo from ASCO/X
Jul 14, 2024, 02:56
Belamaf-based triplet regimens are effective in patients with R/R multiple myeloma – ASCO
ASCO shared on X:
“The DREAMM-7 and DREAMM-8 studies established the effectiveness of belamaf-based triplet regimens in patients with R/R MM who had received ≥1 prior line of therapy.
Ben Derman examines the potential of belamaf + Vd and belamaf + Pd for ASCO Daily News.”
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19